OptimizeRx Corporation provided preliminary financial guidance for the third quarter ended September 30, 2023. For the third quarter, the company expects revenue between $15.2 million and $15.5 million. Net loss is expected to be in the range of $4.1 million to $4.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.12 USD | +15.00% | +8.58% | -29.28% |
Apr. 16 | Earnings Flash (OPRX) OPTIMIZERX CORPORATION Posts Q4 Revenue $28.4M | MT |
Apr. 16 | Earnings Flash (OPRX) OPTIMIZERX CORPORATION Posts Q4 EPS $0.26 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.28% | 184M | |
+18.66% | 414B | |
+15.27% | 242B | |
+12.15% | 144B | |
+20.63% | 104B | |
+17.19% | 83.87B | |
+54.11% | 57.64B | |
+33.59% | 53.37B | |
+6.02% | 37.83B | |
+15.88% | 32.51B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Provides Preliminary Financial Guidance for the Third Quarter Ended September 30, 2023